Cadence Production Remains at Full Capacity

Cadence ( has maintained stable production output as it navigates the COVID-19 challenges. Production at all of Cadence’s five facilities remains at full capacity, with no significant supply disruptions. 

All Cadence employees remain safe, with no known infection or exposure. The company has created a response team that meets daily to address the ongoing situation. Extensive social-distancing practices are in place companywide, as well as employee-travel and visitor restrictions. 

Employee safety is our top priority while we continue to serve our customers and the patients who depend on the critical health-care products that we provide,” said CEO Alan Connor. “I am truly humbled by the effort, thoughtfulness, creativity and empathy that Cadence team members are exhibiting. We stand ready to support our customers and continue to deliver critical medical products through this unprecedented time.”